机构:[1]Department of Respiratory Medicine, The Fourth Affiliated Hospital of Kunming Medical University, The Second People's Hospital of Yunnan Province, Kunming, 650021,Yunnan, China[2]College of Pharmacy, Kunming Medical University, Kunming, 650500, Yunnan, China[3]First Department of Respiratory Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China内科科室呼吸内科呼吸与危重症一科昆明医科大学附属第一医院
Phosphatase and tensin homolog (PTEN) plays an important role in the pathogenesis of hypoxic pulmonary hypertension (HPH). A decrease in PTEN expression is associated with the hypermethylation of its promoter. However, whether the demethylation of the PTEN gene could attenuate HPH remains unknown. 5-Aza-2 '-deoxycytidine (5-Aza-dC) is a DNA methyltransferase (DNMT) inhibitor. The present study was designed to investigate the effects and mechanisms of 5-Aza-dC on HPH. The proliferation, migration and apoptosis of rat pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia and treated with 5-Aza-dC were detected. The expression of PTEN and DNMTs and the PTEN methylation status of PASMCs were detected. SD rats were randomly divided into normal group, hypoxia group and hypoxia + 5-Aza-dC group. The expression of PTEN was decreased, the expression of DNMTs was increased, and the methylation status of PTEN was increased in hypoxia-induced PASMCs. However, 5-Aza-dC can rescue the decreased PTEN, inhibit DNMT levels in a dose-dependent manner and suppress PTEN methylation. Furthermore, the demethylation of PTEN, which was induced by 5-Aza-dC, inhibited the proliferation, migration and promoted apoptosis in PASMCs. In vivo studies further demonstrated that the expression of PTEN, mean pulmonary artery pressure and right ventricular hypertrophy index in HPH rats was attenuated by 5-Aza-dC. 5-Aza-dC also suppressed the expression of DNMTs and PTEN methylation in the lungs of HPH rats. These results indicated that PTEN promoter methylation status is involved in HPH. 5-Aza-dC, as a DNMT inhibitor, has the potential to attenuate HPH via demethylation of the PTEN promoter.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81560694, 81760015, 81360049]; "Special and Joint Program" of Yunnan Provincial Science and Technology Department [2018FE001 (-2-6), 2017FE467 (-094)]; Kunming Medical University [2018FE001 (-2-6), 2017FE467 (-094)]; Yunnan health training project of high level talents [D-201627]; Young Academic and Technical Leaders of Yunnan Province [2017HB053]
第一作者机构:[1]Department of Respiratory Medicine, The Fourth Affiliated Hospital of Kunming Medical University, The Second People's Hospital of Yunnan Province, Kunming, 650021,Yunnan, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Respiratory Medicine, The Fourth Affiliated Hospital of Kunming Medical University, The Second People's Hospital of Yunnan Province, Kunming, 650021,Yunnan, China[3]First Department of Respiratory Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, Yunnan, China[*1]Department of Respiratory Medicine, The Fourth Affiliated Hospital of Kunming Medical University, The Second People's Hospital of Yunnan Province, No. 176, Qingnian Road, Kunming, 650021, Yunnan, China.[*2]Department of Respiratory Medicine, The First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Kunming,650032, Yunnan, China.
推荐引用方式(GB/T 7714):
Xing Xi-Qian,Li Bo,Xu Shuang-Lan,et al.5-Aza-2 '-deoxycytidine, a DNA methylation inhibitor, attenuates hypoxic pulmonary hypertension via demethylation of the PTEN promoter[J].EUROPEAN JOURNAL OF PHARMACOLOGY.2019,855:227-234.doi:10.1016/j.ejphar.2019.05.021.
APA:
Xing, Xi-Qian,Li, Bo,Xu, Shuang-Lan,Zhang, Chun-Fang,Liu, Jie...&Yang, Jiao.(2019).5-Aza-2 '-deoxycytidine, a DNA methylation inhibitor, attenuates hypoxic pulmonary hypertension via demethylation of the PTEN promoter.EUROPEAN JOURNAL OF PHARMACOLOGY,855,
MLA:
Xing, Xi-Qian,et al."5-Aza-2 '-deoxycytidine, a DNA methylation inhibitor, attenuates hypoxic pulmonary hypertension via demethylation of the PTEN promoter".EUROPEAN JOURNAL OF PHARMACOLOGY 855.(2019):227-234